Skip to main content

Table 2 Univariate and Multivariate COX Regression for Overall Survival

From: Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma

Variables Univariate Multivariate
P value HR(95% CI) P value HR(95% CI)
Age 0.277 0.684(0.345–1.357)   
NLR ≥ 2.4 0.362 1.375(0.694–2.725)   
PLR ≥ 108 0.098 1.783(0.898–3.539)   
SII ≥ 340 0.020 2.308(1.140–4.676) 0.028 2.211(1.089–4.489)
Child Pugh score 6 0.248 1.549(0.737–3.254)   
ALBI grade 2 0.055 2.004(0.987–4.072)   
AFP ≥ 400 ng/mL 0.008 2.849(1.309–6.200) 0.011 2.750(1.259–6.010)
PIVKA-II ≥ 1000 mAU/mL 0.079 2.122(0.917–4.913)   
BCLC stage C 0.527 0.787(0.375–1.652)   
Vascular invasion 0.171 1.652(0.805–3.391)   
Extrahepatic metastasis 0.450 0.770(0.390–1.518)   
  1. AFP alpha-fetoprotein, ALBI albumin–bilirubin, BCLC Barcelona Clinic Liver Cancer, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, PIVKA protein induced by vitamin K absence or antagonist, SII systemic immune-inflammation index